Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
08/2003
08/07/2003WO2003063911A1 Decoy-containing pharmaceutical compositions and method of using the same
08/07/2003WO2003063908A1 Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
08/07/2003WO2003063875A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis
08/07/2003WO2003063873A1 Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2, 3-d)-pyrimidine for treating of urinary incontinence
08/07/2003WO2003063861A1 Fibrosis inhibitor
08/07/2003WO2003063859A1 Suppression of cartilage degradation via the estrogen receptor
08/07/2003WO2003063852A1 Therapeutic agent for urinary incontinence
08/07/2003WO2003063834A1 Multi-stage oral drug controlled-release system
08/07/2003WO2003063796A2 Heterocyclic arylsulfonamidobenzylic compounds
08/07/2003WO2002055541A3 Peptides having inhibiting activity on the production of nitric oxide
08/07/2003WO2002002593A3 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
08/07/2003WO2002000172A3 Methods for using tetanus toxin for benificial purposes in animals (mammals)
08/07/2003US20030149998 Nucleotide sequences coding orphan receptors/membrane proteins OM-10 and UP-11 for detecting modulators of inflammation, nervous system activity and infection; antitumor/antiinflammatory agents; gene expression inhibition
08/07/2003US20030149277 Triarylimidazole derivatives as cytokine inhibitors
08/07/2003US20030149268 Administering non-steroidal 9-pyrido(3,2-g)quinoline compounds to the mammal for affecting androgen receptor activity
08/07/2003US20030149266 Administering to a patient (a warm blooded animal, such as man) an effective amount of a pyrimidine derivative for treating cancer, cell proliferation, and inhibition of focal adhesion kinase effect
08/07/2003US20030149237 G-protein coupled receptor for treatment and prevention of eating, cancer, autoimmune, vision and nervous sytem disorders; antiinflammatory agents
08/07/2003US20030149113 Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
08/07/2003US20030149110 For use as as neuro-protective agents for therapy of conditions such as stroke, cerebral ischemia, central nervous system trauma, hypoglycemia, anxiety, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine
08/07/2003US20030149108 Linked biaryl compounds
08/07/2003US20030149107 For therapy of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis
08/07/2003US20030149105 Suplatast tosilate crystals
08/07/2003US20030149094 Compositions comprising ether compounds and pharmaceutical uses therefor
08/07/2003US20030149081 For therapy and prophylaxis of asthma, seasonal and perennial allergic rhinitis, sinusitus, conjunctivitis, food allergy, scombroid poisoning, psoriasis, urticaria, pruritus, eczema, inflammatory bowel disease, atherosclerosis
08/07/2003US20030149058 Use of dipyridamole or mopidamol for treatment and prevention of fibrin-dependent microcirculation disorders
08/07/2003US20030149057 Anti-cancer compounds
08/07/2003US20030149056 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases
08/07/2003US20030149051 For therapy of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, cancer, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks
08/07/2003US20030149048 For therapy of hyperproliferative disorder in a mammal
08/07/2003US20030149047 Novel compounds
08/07/2003US20030149043 N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
08/07/2003US20030149039 For therapy of disease responsive to antagonist modulation of the Neurokinin-1 (NK-1) receptor in a patient
08/07/2003US20030149037 For therapy and prophylaxis of inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, neurodegenerative diseases, allergies, reperfusion/ischemia in stroke, heart attacks, etc.
08/07/2003US20030149033 For prophylaxis and therapy of cerebrovascular diseases such as cerebral ischemia, stroke, reperfusion damage, brain trauma, edemas, cerebral thrombosis, dementia and Alzheimer's diseass
08/07/2003US20030149010 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
08/07/2003US20030149001 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
08/07/2003US20030148961 Peptidyl ketones as inhibitors of DPIV
08/07/2003US20030148947 MIP as a research tool for identification, characterization and purification of molecules involved in cellular transport and osmotic regulation; agonists/antagonists; vision defects; anitinflammatory agents; nervous system and kidney disorders
08/07/2003US20030148934 Human growth factor modulators (GFMO) polynucleotides which identify and encode GFMO; amino acid sequences, expression vectors, host cells, antibodies, agonists, and antagonists; anticarcinogenic agents; fibrotic disorders
08/07/2003US20030148394 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058, or 6351 molecules
08/07/2003US20030148327 Nucleic acid of given sequence; oligonucleotides and oligomers for detecting the cytosine methylation of genes; tumors and cancer
08/07/2003US20030148326 Diagnosis of diseases associated with dna transcription
08/07/2003US20030148271 Given amino acid sequence; expression vectors, host cells; diagnosis, prevention and treatment of diseases associated with expression of the kallikrein
08/07/2003US20030148099 Microcapsules having high carotenoid content
08/07/2003US20030147955 Dry .1 to 1.5% tamsulosin active material and excipients; treating benign prostatic hyperplasia
08/07/2003US20030147950 .1-10 mg of tamsulosin with an enteric coating and has a dissolution profile in media of </= 60% at 2 hours; reduced or no food effect
08/07/2003US20030147937 Di-myo-inositol phosphate, cyclic 2,3 diphosphoglycerate, 1,1-di- glycerol phosphate, mannosylglycerate, mannosyl glyceramide and/or di-mannosyl-di-inositol phosphate; protecting organisms, organs, tissues, cells from oxidation
08/07/2003US20030147903 ABC transport polynucleotides, polypeptides and antibodies
08/07/2003CA2714295A1 Desaturase genes, enzymes encoded thereby, and uses thereof
08/07/2003CA2474908A1 Aggrecanase molecules
08/07/2003CA2474852A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis
08/07/2003CA2474851A1 Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2, 3-d)-pyrimidine for treating of urinary incontinence
08/07/2003CA2474702A1 Heterocyclic arylsulfonamidobenzylic compounds
08/07/2003CA2474649A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
08/07/2003CA2474616A1 Human monoclonal antibodies to prostate specific membrane antigen (psma)
08/07/2003CA2474588A1 2'-halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
08/07/2003CA2473803A1 Substituted indoles as alpha-1 agonists
08/07/2003CA2473797A1 Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
08/07/2003CA2473249A1 New corticosteroids
08/07/2003CA2473128A1 Genetic polymorphisms in the preprotachykinin gene
08/07/2003CA2466915A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor
08/07/2003CA2465265A1 Degp protease: cleavage site identification and proteolysis of a natural target in e. coli
08/06/2003EP1333028A1 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
08/06/2003EP1332372A2 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
08/06/2003EP1332146A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1332144A1 Indole derivatives as pde5-inhibitors
08/06/2003EP1332136A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
08/06/2003EP1331943A2 Nucleic acid molecules and polypeptides for immune modulation
08/06/2003EP1331935A2 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
08/06/2003EP0804419B1 Quinoline derivatives as tachykinin nk 3 receptor antagonists
08/06/2003CN1434832A DNA for encoding the RGI polypeptide
08/06/2003CN1434825A Novel imidazo ÒÇö1,3,5ÒÇòtriazinones and the use thereof
08/06/2003CN1434823A 3-thiazol-4-yl-pyprolidine derivatives as AMP-specific phosphodiesterase inhibitors
08/06/2003CN1434820A Cyclic AMP-specific phosphodiesterase inhibitors
08/06/2003CN1434818A Novel compounds
08/06/2003CN1434817A Pyrazole cyclic AMP-specific PDE inhibitors
08/06/2003CN1434813A Pyrrolidine derivatives cyclic AMP-specific phosphodiesterase inhibitors
08/06/2003CN1434811A New p2†ù7 receptor antagonists for use in the treatment of inflammatory immune or cardiovascular diseases
08/06/2003CN1434805A 选择性神经激肽拮抗剂 Selective neurokinin antagonists
08/06/2003CN1434801A Substited 8-anylquinoline phosphodiesterase-4 inhibitors
08/06/2003CN1434799A Cyclic amp-specific phosphodiesterase inhibitors
08/06/2003CN1434798A Pyrrolidines which inhibit CAMP-specific PDE
08/06/2003CN1434797A Hydrazone and oxime derivatives of pyrrolidine as AMP-specific phosphodiesterase inhibitons
08/06/2003CN1434794A Adamantane derivatives
08/06/2003CN1434712A Nitrosated and nitrosylated cyclooxygenase-2 inhibitors compositions and methods of use
08/06/2003CN1434705A Use of hydroxide-releasing agents as skin permeation enhancers
08/06/2003CN1433801A Medicine for treating nephrosis
08/06/2003CN1433784A Traditional Chinese medicine composition for treating choleithiasis
08/06/2003CN1433761A Piperazine ferulate slow-released, control-released agent
08/06/2003CN1117092C Azadicyclic compound, its medicinal composition and medicinal use
08/06/2003CN1117077C 6-phenylpyridyl-2-amine derivatives useful asNOS inhibitors
08/06/2003CN1116877C Carboprost methylate preparation able to be absorbed via oral musoca and its preparing process
08/05/2003US6603008 Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents
08/05/2003US6602888 Use of α1C specific compounds to treat benign prostatic hyperplasia
08/05/2003US6602881 Anti-inflammatory uses of manzamines
08/05/2003US6602878 Acylquanidine derivatives, method for preparing same, application as medicines and pharmaceutical compositions containing them
08/05/2003US6602876 Adhesion receptor antagonists
08/05/2003US6602867 Triazole compounds with dopamine-D3-receptor affinity
08/05/2003US6602525 Compositions comprising nitrofurantoin and uva ursi
08/05/2003US6602501 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
1 ... 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 ... 562